CA2516786A1 - Treatment of excessive osteolyisis with indolinone compounds - Google Patents

Treatment of excessive osteolyisis with indolinone compounds Download PDF

Info

Publication number
CA2516786A1
CA2516786A1 CA002516786A CA2516786A CA2516786A1 CA 2516786 A1 CA2516786 A1 CA 2516786A1 CA 002516786 A CA002516786 A CA 002516786A CA 2516786 A CA2516786 A CA 2516786A CA 2516786 A1 CA2516786 A1 CA 2516786A1
Authority
CA
Canada
Prior art keywords
group
alkyl
heteroaryl
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002516786A
Other languages
English (en)
French (fr)
Inventor
Lesley Murray
Anne-Marie O'farrell
Tinya Abrams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sugen LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2516786A1 publication Critical patent/CA2516786A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA002516786A 2003-02-24 2004-02-23 Treatment of excessive osteolyisis with indolinone compounds Abandoned CA2516786A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44886103P 2003-02-24 2003-02-24
US60/448,861 2003-02-24
US10/780,917 2004-02-19
US10/780,917 US20040209937A1 (en) 2003-02-24 2004-02-19 Treatment of excessive osteolysis with indolinone compounds
PCT/US2004/005283 WO2004075775A2 (en) 2003-02-24 2004-02-23 Treatment of excessive osteolyisis with indolinone compounds

Publications (1)

Publication Number Publication Date
CA2516786A1 true CA2516786A1 (en) 2004-09-10

Family

ID=32930497

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002516786A Abandoned CA2516786A1 (en) 2003-02-24 2004-02-23 Treatment of excessive osteolyisis with indolinone compounds

Country Status (11)

Country Link
US (1) US20040209937A1 (cg-RX-API-DMAC7.html)
EP (1) EP1599207A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006518756A (cg-RX-API-DMAC7.html)
KR (1) KR20050113612A (cg-RX-API-DMAC7.html)
AU (1) AU2004216188A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0407793A (cg-RX-API-DMAC7.html)
CA (1) CA2516786A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05008961A (cg-RX-API-DMAC7.html)
NZ (1) NZ541825A (cg-RX-API-DMAC7.html)
PL (1) PL378762A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004075775A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006245421A1 (en) * 2005-05-12 2006-11-16 Pfizer Inc. Anticancer combination therapy using sunitinib malate
RU2399619C2 (ru) * 2005-09-19 2010-09-20 Пфайзер Продактс Инк. Твердые солевые формы замещенного пирролом 2-индолинона
CN101379400A (zh) * 2005-12-22 2009-03-04 诺华有限公司 可溶性人m-csf受体及其应用
CN101367801B (zh) * 2007-08-15 2011-01-12 上海恒瑞医药有限公司 吡咯并六元n杂环羟基吗啡啉类衍生物的制备方法及其在医药上的应用
EP2318364A2 (en) * 2008-07-02 2011-05-11 Generics [UK] Limited Preparation of 3-pyrrole substituted 2-indolinone derivatives
JP2011527330A (ja) * 2008-07-10 2011-10-27 ジェネリクス・(ユーケー)・リミテッド スニチニブリンゴ酸塩の結晶形の調製方法
CN102239163A (zh) * 2008-07-24 2011-11-09 特瓦制药工业有限公司 通过乙酸舒尼替尼和它们的多晶型物制备苹果酸舒尼替尼的方法
CA2731605A1 (en) * 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
EP2181991A1 (en) * 2008-10-28 2010-05-05 LEK Pharmaceuticals D.D. Novel salts of sunitinib
EP2186809A1 (en) * 2008-11-13 2010-05-19 LEK Pharmaceuticals D.D. New crystal form of sunitinib malate
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US10898211B2 (en) 2015-01-14 2021-01-26 Crossroads Extremity Systems, Llc Opening and closing wedge osteotomy guide and method
US10292713B2 (en) 2015-01-28 2019-05-21 First Ray, LLC Freeform tri-planar osteotomy guide and method
US10376268B2 (en) 2015-02-19 2019-08-13 First Ray, LLC Indexed tri-planar osteotomy guide and method
CN109311811B (zh) * 2016-06-09 2022-09-09 有机合成药品工业株式会社 4-(哌啶-4-基)吗啉的制备方法
WO2021021640A1 (en) 2019-07-26 2021-02-04 Crossroads Extremity Systems, Llc Bone repositioning guide system and procedure
US11304735B2 (en) 2020-02-19 2022-04-19 Crossroads Extremity Systems, Llc Systems and methods for Lapidus repair of bunions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020751B1 (hr) * 2000-02-15 2011-01-31 Sugen Pirolom supstituirani 2-indolinoni kao inhibitori protein kinaze
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2005508953A (ja) * 2001-10-10 2005-04-07 スージェン・インコーポレーテッド キナーゼ阻害剤としての3−[4−(置換ヘテロサイクリル)−ピロール−2−イルメチリデン]−2−インドリノン誘導体
AU2003233576A1 (en) * 2002-05-17 2003-12-02 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals

Also Published As

Publication number Publication date
US20040209937A1 (en) 2004-10-21
EP1599207A2 (en) 2005-11-30
AU2004216188A1 (en) 2004-09-10
BRPI0407793A (pt) 2006-02-14
MXPA05008961A (es) 2005-11-04
WO2004075775A2 (en) 2004-09-10
PL378762A1 (pl) 2006-05-15
WO2004075775A3 (en) 2005-04-14
NZ541825A (en) 2008-11-28
KR20050113612A (ko) 2005-12-02
JP2006518756A (ja) 2006-08-17

Similar Documents

Publication Publication Date Title
AU2002360314B2 (en) Treatment of acute myeloid leukemia with indolinone compounds
US20040152759A1 (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
CN102271681B (zh) Cxcr7调节剂
US20040209937A1 (en) Treatment of excessive osteolysis with indolinone compounds
DK2663564T3 (en) IMIDAZO [4,5-C] QUINOLIN-2-ON COMPOUND AND ITS USE AS PI3-KINASE / MTOR DUAL INHIBITOR
JP5956653B2 (ja) 1−(5−tert−ブチル−2−フェニル−2H−ピラゾール−3−イル)−3−[2−フルオロ−4−(1−メチル−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−B]ピリジン−7−イルオキシ)−フェニル]−尿素および関連化合物ならびに治療におけるそれらの使用
JP2023541522A (ja) 低分子量タンパク質分解物質及びその適用
CN112375078A (zh) 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
JP2012121930A (ja) イミダゾ[4,5−d]ピリミジン、それらの使用および調製方法
EA005996B1 (ru) Пирролзамещенный 2-индолинон, фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
US20150313923A1 (en) Phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
ZA200506371B (en) Treatment of excessive osteolysis with indolinone compounds
TWI699366B (zh) 治療或預防癌症的化合物
HK1120406A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
HK40041466A (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof

Legal Events

Date Code Title Description
FZDE Discontinued